Influence of *APOA5* locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects

Sha Hua[1], Chuanxiang Ma[2], Jun Zhang[3], Jing Li[1], Weiwei Wu[1], Ning Xu[4], Guanghua Luo[3,*], Jianrong Zhao[1,*]

[1]Department of Cardiology, Ruijin Hospital Luwan Branch, School of Medicine, Shanghai Jiao Tong University, South Chongqing Rd. No.149, Shanghai 200020, China.

[2]Department of Pathology, The Affiliated Hospital of Weifang Medical University, Weifang 261000, China.

[3]Comprehensive Laboratory, Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, China.

[4]Section of Clinical Chemistry and Pharmacology, Institute of Laboratory Medicine, Lund University, S-221 85 Lund, Sweden.

[*]Corresponding authors: Guanghua Luo (shineroar@163.com) or Jianrong Zhao (drzjr@126.com)

Running title: *APOA5* and statin interactions

Abbreviations: ApoA5, apolipoprotein A5; BMI, body mass index; FFA, free fatty acids; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); SNP, single nucleotide polymorphism; T2D, type 2 diabetes; Tc, total cholesterol; Tg, triglycerides.

Abstract

Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is *APOA5* which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored *APOA5*-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5-10 mg/day), atorvastatin (10-20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the *APOA5* promoter SNP rs662799 (-1131T>C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers, confirming the higher potency of the low-dose rosuvastatin. Reductions in LDL cholesterol were influenced by the *APOA5* genotype in all three treatment groups. By contrast, changes in HDL cholesterol and triglycerides were only affected by the *APOA5* genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Our results support earlier findings indicating that rosuvastatin is a better treatment option and that future studies should consider stratifying subjects not only by genetic background but also by statin type.

Keywords: *APOA5* genotype, statins, triglycerides, dyslipidemia

Introduction

Although statins are the most prescribed class of drugs worldwide for prevention of various cardiovascular diseases, about one third of patients do not respond well to this therapy with respect to the lipid-lowering effect, suggesting that pharmacogenomics (1) or other environmental factors such as diet (2) or the gut microbiome (3) may play substantial roles. To date, genome-wide association studies have identified at least 39 genes that are associated with statin treatment efficacy (4). Most of these genes are involved in either the direct pharmacokinetic handling of statins or in lipid metabolism pathways especially these involving cholesterol, the main target of statin therapy (5). However, accumulating evidence indicates that statins can also lower levels of triglycerides, potentially through altering degradation of apolipoprotein B (ApoB) and related very low-density lipoprotein (VLDL) balance, although the precise mechanism remains unclear (6-8). One gene of particular interest within this context is *APOA5*, which has been repeatedly associated with the high inter-individual variations of serum triglycerides in all reported populations (9-13) since its identification in 2001 (14, 15). According to one estimation, the *APOA5* promoter SNP rs662799 (-1131T>C) alone can contribute to 6.2% of the genetic component of hypertriglyceridemia (16). Of note, the minor C allele is much more common in the Asian population (26%-40%) than in Caucasians (only ~8%) (9). In addition, accumulating evidence suggests that this gene also confers risk for cardiovascular disease (10) and myocardial infarction (17). Although previous studies have suggested a link between this gene and statin treatment (18, 19), the impact of the *APOA5* locus on the clinical responses to different types of statin therapy is less clear.

Here, we performed a pilot study to explore *APOA5*-statin interactions in 195 Chinese subjects randomized to rosuvastatin, atorvastatin, or simvastatin therapy for 12 weeks. To address whether the clinical responses of three types of statins differ between subjects with the same *APOA5* genetic background, we genotyped *APOA5* rs662799 SNP and measured the fasting plasma concentrations of triglycerides, cholesterols, free fatty acids, and four apolipoproteins both before and after statin treatments.

Materials and Methods

Study subjects and study design

3

We recruited 195 patients at Shanghai Ruijin Hospital Luwan Branch (affiliated to Shanghai Jiaotong University). In brief, the inclusion criteria were: (i) aged 18 years or older; (ii) newly diagnosed with dyslipidemia and/or increased risk of atherosclerotic cardiovascular disease and recommended to receive statins according to the 2013 American College of Cardiology (ACC) and the American Heart Association (AHA) Blood Cholesterol Guidelines (20); (iii) absence of major systematic diseases such as malignancy; and (iv) without medication (especially antibiotics) in the previous three months except antihypertensive therapy.

The subjects were then randomly divided into three treatment arms to receive rosuvastatin (5-10 mg per day), atorvastatin (10-20 mg per day), or simvastatin (40 mg per day) for 12 weeks. To achieve comparable clinical efficacies in response to the three statins, the different statin doses were selected based on both clinical practice and evidence suggesting that each rosuvastatin dose is equivalent to 3-3.5 times of atorvastatin and 7-8 times of simvastatin (at least in terms of cholesterol reduction) (18). All treatments were tolerated with no side effects reported.

Written informed consent was obtained from all the study participants. This study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by Ethics Committee of Shanghai Ruijin Hospital Luwan Branch. Complete clinical trial registration is deposited at chictr.org.cn (ChiCTR-RRC-16010131).

Laboratory analyses

Fasting plasma concentrations of triglycerides, total cholesterol, HDL cholesterol (HDLc), LDL cholesterol (LDLc), free fatty acids (FFA), and three different apolipoproteins (ApoA1, ApoB-100, ApoE) and lipoprotein(a) were measured by enzymatic methods using a Beckman Coulter Chemistry Analyzer AU5800 Series (United States) at both baseline and 12 weeks after treatments.

DNA was isolated using the TIANamp Blood DNA kit (purchased from Tiangen, Beijing, China) and individual *APOA5* variants (-1131T>C – rs662799) were genotyped using a base-quenched probe method combined with polymerase chain reaction (PCR) as described before (21). In brief, a 19-nt probe (5'-GGCAAATCTCACTTTCGCT-3') containing the targeted SNP site was first conjugated with 6-carboxyfluorescein and then hybridized to its complementary target sequence from PCR amplification. An analytical melting program that involves heating the amplicon/probe heteroduplex will produce different fluorescence curves depending on the genotypes of rs662799. Both the probe and primers (forward: 5'-AGGAGTGTGGTAGAAAGACCTGTTG-3'; reverse:

5'-AACTACCCAGAGTCACTGTGTCCC-3') used were synthesized by Sangon (Shanghai, China).

Statistical analysis

Statistical differences between groups were estimated by Wilcox rank-sum test (between two groups), Kruskal-Wallis test (among three groups) for continuous variables or by Chi-square test for categorical variables. Different linear regression models were also built and compared using Chi-square test to confirm the effect of *APOA5* genotype on different biomarkers and adjusted for contributions from type 2 diabetes and sex. Associations between apolipoproteins and concentrations of LDLc and HDLc were measured by Spearman's rank correlation analysis. Hardy-Weinberg Equilibrium was accessed by exact test based on R package "HardyWeinberg" (22). Raw P values were adjusted by the Benjamini-Hochberg method (23) with a false discovery rate of 5%. A power of 99.98% was obtained using pwr package (24) for this study based on 65 patients with paired design, 5% significance, and an estimated effect size of 0.7 for statin in reducing LDL cholesterol (25, 26). All statistical tests and data visualizations as well as the stratified randomization process by considering BMI as covariate were performed under the R environment (27).

Results and discussion

Baseline characteristics

The minor C allele frequency of *APOA5* rs662799 SNP in our cohort was 30%, consistent with other reports based on larger Chinese cohorts (9, 28); the genotype frequency of *APOA5* was in agreement with Hardy-Weinberg equilibrium ($n = 13$, 91 and 91 for C/C, T/C, and T/T allele carriers, respectively; P=0.171). T/C and C/C subjects were pooled as T(C)/C ($n = 104$) for further analyses to increase the power. With the exception of ApoE, there were no significant baseline differences between the treatment arms, including the frequencies of the T(C)/C and T/T genotypes (P=0.342) (**Table 1**). These data suggest that the treatment groups are in general homogeneous and this study design is suitable for addressing the relationship between *APOA5* variations and the clinical responses of three statins. When dividing the subjects by genotype, the T(C)/C allele carriers had significantly higher plasma triglycerides than T/T carriers at baseline (**Table 1**), in agreement with previous studies (9, 10, 28).

We also noted that subjects with the T(C)/C genotype had higher LDLc than T/T carriers at baseline (**Table 1**); these findings were consistent with observations in a larger cohort (10) but an earlier study in Chinese men did not observe significant *APOA5*-LDLc interactions (9). It is not clear how *APOA5* variants affect LDLc as ApoA5 has only been detected on HDL and VLDL and not on LDL particles (29). However, ApoA5 has been shown to directly interact with members of the LDL-receptor family (30). In addition, an earlier study has shown a significant association between the *APOA5* rs662799 SNP and increased risk of early-onset myocardial infarction even after adjusting for triglycerides (31), providing further evidence that this SNP may simultaneously affect other atherogenic lipids such as LDLc. It is also possible that this SNP is in complete linkage disequilibrium with other polymorphism(s) that can explain the observed LDLc levels.

Rosuvastatin-induced changes in HDLc and triglycerides are not affected by APOA5 genotype

We next compared the clinical efficacies (in terms of cholesterol, triglyceride, and apolipoprotein changes) of the statins. As expected, all three statins promoted significant reductions in total cholesterol, ApoB, LDLc, ApoE and triglycerides and significant increases in ApoA1 and HDLc (**Fig. 1A**). However, there were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers after adjusting for multiple testing (false discovery rate 5%), confirming that the response to 5-10 mg of rosuvastatin is similar to that of 10-20 mg atorvastatin and 40 mg of simvastatin as suggested previously (18). In agreement, results from a meta-analysis (32), comparative pharmacology (33) and the MERCURY II clinical trial (29) have all shown that rosuvastatin is more potent than the other statins and thus lower doses can be used to achieve equivalent responses.

To determine how *APOA5* variations affected the clinical responses of the three statins, we investigated how changes in the biomarker concentrations in response to each statin varied between subjects with the T(C)/C or T/T genotype (**Fig. 1B-E; Supplementary Table S1**). Genotype did not affect the changes in total cholesterol (**Fig. 1B**), apolipoproteins, FFA or lipoprotein(a) (data not shown) in response to any of the three statins. However, patients homozygous for the major T allele (T/T genotype) not only exhibited lower baseline LDLc levels (**Table 1**) but also demonstrated significantly larger LDLc reductions compared with the C allele carriers, independent of the type of statin used (**Fig. 1C**). By contrast, rosuvastatin-induced changes in HDLc and triglycerides showed little variation between patients with the T(C)/C and

T/T genotypes whereas changes in HDLc and triglycerides were more pronounced in T/T compared with T(C)/T carriers upon atorvastatin or simvastatin treatment (**Fig. 1D,E**). These data suggest that rosuvastatin-induced responses may be less affected by *APOA5* variations than the other two statins. The results were still valid after adjusting for type 2 diabetes and sex (**Supplementary Table S2**). It has been suggested that the hydrophilic rosuvastatin is largely excreted unchanged (35) whereas the other two lipophilic statins undergo substantial metabolism by the CYP450 pathways and thus are more affected by gene polymorphisms (34, 36), consistent with our findings. Additionally, rosuvastatin differs from the other statins by its stronger binding to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, lower systemic bioavailability, longer elimination half-life (33) and greater hepatoselectivity (34). These physio-biochemical differences may also potentially contribute to the different treatment responses according to genotype. However, to fully understand how *APOA5* affects statin treatments, in-depth characterizations of its functional role are needed.

Statin-APOA5 interactions altered the correlations between apolipoproteins and LDLc/HDLc

Although most therapies to reduce cardiovascular disease risk currently focus on reduction of LDLc and triglycerides, atherogenic proteins such as ApoB have also been suggested to have great predictive value (37). Accordingly, the American Diabetes Association and the American College of Cardiology Foundation recommend that therapy for patients with high cardiovascular disease risk should aim to lower ApoB concentrations to below 90 mg/dl in addition to reducing LDLc levels (38). To address whether the well-known strong associations between ApoB and LDLc both before and after stain treatments (37) differ among patients with different *APOA5* genotypes, we additionally analyzed ApoB-LDLc correlations within each *APOA5* SNP subgroup. Before treatment, strong and significant positive correlations were observed between ApoB and LDLc for both T(C)/C (Spearman coefficient rho= 0.55; *P*<0.001) and T/T carriers (rho=0.78; *P*<0.001; **Fig. 2A**). After treatment, a comparable strong correlation only existed for the C allele carriers (rho=0.50; *P*<0.001; **Fig. 2B**). In contrast, the dramatic decrease in the ApoB-LDLc correlation among T/T carriers (from 0.78 to 0.44) indicates the statin-induced reduction of ApoB in absolute values was much smaller than reduction of LDLc. Thus, further treatment to reduce the levels of ApoB even after achieving recommended LDLc reductions could be beneficial in T/T carriers. Similar observations were found between ApoA1 and HDLc (**Supplementary Figure S1**).

7

Conclusion

In summary, our results show that low-dose rosuvastatin achieves improvements in clinical responses that are comparable to those observed with higher doses of atorvastatin and simvastatin but are less affected by *APOA5* genotype. These findings support the growing recognition that rosuvastatin is a potentially better treatment option for patients with dyslipidemia and/or at high risk of cardiovascular diseases. In addition, integrated efforts, such as the NIH Pharmacogenetics Research Network (39), should be encouraged in the era of precision medicine to accelerate pharmacogenetics or pharmacogenomics research. Future studies should also consider stratifying populations by genetic background and by statin type.

Conflict of Interest

The authors declare no conflict of interest.

Author contributions

S.H., G.L., N.X. and J.Z. designed the study; S.H. performed the randomization process and clinical intervention; J.L. and W.W. enrolled participants and measured the lipids and apolipoproteins; J.Z. and G.L. performed the genotyping analysis; S.H., C.M., J.L. and W.W. collected and analyzed the data; S.H., C.M, G.L. and J.Z. wrote the manuscript.

Acknowledgements

References

1.   Postmus, I., S. Trompet, H. A. Deshmukh, M. R. Barnes, X. Li, H. R. Warren, D. I. Chasman, K. Zhou, B. J. Arsenault, L. A. Donnelly, K. L. Wiggins, C. L. Avery, P. Griffin, Q. Feng, K. D. Taylor, G. Li, D. S. Evans, A. V. Smith, C. E. de Keyser, A. D. Johnson, A. J. de Craen, D. J. Stott, B. M. Buckley, I. Ford, R. G. Westendorp, P. E. Slagboom, N. Sattar, P. B. Munroe, P. Sever, N. Poulter, A. Stanton, D. C. Shields, E. O'Brien, S. Shaw-

8

Hawkins, Y. D. Chen, D. A. Nickerson, J. D. Smith, M. P. Dube, S. M. Boekholdt, G. K. Hovingh, J. J. Kastelein, P. M. McKeigue, J. Betteridge, A. Neil, P. N. Durrington, A. Doney, F. Carr, A. Morris, M. I. McCarthy, L. Groop, E. Ahlqvist, C. Welcome Trust Case Control, J. C. Bis, K. Rice, N. L. Smith, T. Lumley, E. A. Whitsel, T. Sturmer, E. Boerwinkle, J. S. Ngwa, C. J. O'Donnell, R. S. Vasan, W. Q. Wei, R. A. Wilke, C. T. Liu, F. Sun, X. Guo, S. R. Heckbert, W. Post, N. Sotoodehnia, A. M. Arnold, J. M. Stafford, J. Ding, D. M. Herrington, S. B. Kritchevsky, G. Eiriksdottir, L. J. Launer, T. B. Harris, A. Y. Chu, F. Giulianini, J. G. MacFadyen, B. J. Barratt, F. Nyberg, B. H. Stricker, A. G. Uitterlinden, A. Hofman, F. Rivadeneira, V. Emilsson, O. H. Franco, P. M. Ridker, V. Gudnason, Y. Liu, J. C. Denny, C. M. Ballantyne, J. I. Rotter, L. Adrienne Cupples, B. M. Psaty, C. N. Palmer, J. C. Tardif, H. M. Colhoun, G. Hitman, R. M. Krauss, J. Wouter Jukema, and M. J. Caulfield. 2014. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nat Commun* **5**: 5068.

2. Jenkins, D. J., C. W. Kendall, A. Marchie, D. A. Faulkner, J. M. Wong, R. de Souza, A. Emam, T. L. Parker, E. Vidgen, E. A. Trautwein, K. G. Lapsley, R. G. Josse, L. A. Leiter, W. Singer, and P. W. Connelly. 2005. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. *Am J Clin Nutr* **81**: 380-387.

3. Kaddurah-Daouk, R., R. A. Baillie, H. Zhu, Z. B. Zeng, M. M. Wiest, U. T. Nguyen, K. Wojnoonski, S. M. Watkins, M. Trupp, and R. M. Krauss. 2011. Enteric microbiome metabolites correlate with response to simvastatin treatment. *PLoS One* **6**: e25482.

4. Gryn, S. E., and R. A. Hegele. 2014. Pharmacogenomics, lipid disorders, and treatment options. *Clin Pharmacol Ther* **96**: 36-47.

5. Mangravite, L. M., C. F. Thorn, and R. M. Krauss. 2006. Clinical implications of pharmacogenomics of statin treatment. *Pharmacogenomics J* **6**: 360-374.

6. Ginsberg, H. N. 1998. Effects of statins on triglyceride metabolism. *Am J Cardiol* **81**: 32B-35B.

7. Ginsberg, H. N., N. A. Le, M. P. Short, R. Ramakrishnan, and R. J. Desnick. 1987. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. *J Clin Invest* **80**: 1692-1697.

8. Arad, Y., R. Ramakrishnan, and H. N. Ginsberg. 1992. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. *Metabolism: clinical and experimental* **41**: 487-493.

9. Baum, L., B. Tomlinson, and G. N. Thomas. 2003. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. *Clin Genet* **63**: 377-379.

10. Lai, C. Q., S. Demissie, L. A. Cupples, Y. Zhu, X. Adiconis, L. D. Parnell, D. Corella, and J. M. Ordovas. 2004. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. *Journal of lipid research* **45**: 2096-2105.

11.   Hubacek, J. A., V. Lanska, Z. Skodova, V. Adamkova, and R. Poledne. 2008. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. *Eur J Hum Genet* **16**: 135-138.

12.   Son, K. Y., H. Y. Son, J. Chae, J. Hwang, S. Jang, J. M. Yun, B. Cho, J. H. Park, and J. I. Kim. 2015. Genetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men. *Lipids Health Dis* **14**: 105-113.

13.   Ouatou, S., M. Ajjemami, H. Charoute, H. Sefri, N. Ghalim, H. Rhaissi, H. Benrahma, A. Barakat, and H. Rouba. 2014. Association of APOA5 rs662799 and rs3135506 polymorphisms with arterial hypertension in Moroccan patients. *Lipids Health Dis* **13**: 60-68.

14.   van der Vliet, H. N., M. G. Sammels, A. C. Leegwater, J. H. Levels, P. H. Reitsma, W. Boers, and R. A. Chamuleau. 2001. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. *J Biol Chem* **276**: 44512-44520.

15.   Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science* **294**: 169-173.

16.   Hegele, R. A. 2009. Plasma lipoproteins: genetic influences and clinical implications. *Nat Rev Genet* **10**: 109-121.

17.   Do, R., N. O. Stitziel, H. H. Won, A. B. Jorgensen, S. Duga, P. Angelica Merlini, A. Kiezun, M. Farrall, A. Goel, O. Zuk, I. Guella, R. Asselta, L. A. Lange, G. M. Peloso, P. L. Auer, N. E. S. Project, D. Girelli, N. Martinelli, D. N. Farlow, M. A. DePristo, R. Roberts, A. F. Stewart, D. Saleheen, J. Danesh, S. E. Epstein, S. Sivapalaratnam, G. K. Hovingh, J. J. Kastelein, N. J. Samani, H. Schunkert, J. Erdmann, S. H. Shah, W. E. Kraus, R. Davies, M. Nikpay, C. T. Johansen, J. Wang, R. A. Hegele, E. Hechter, W. Marz, M. E. Kleber, J. Huang, A. D. Johnson, M. Li, G. L. Burke, M. Gross, Y. Liu, T. L. Assimes, G. Heiss, E. M. Lange, A. R. Folsom, H. A. Taylor, O. Olivieri, A. Hamsten, R. Clarke, D. F. Reilly, W. Yin, M. A. Rivas, P. Donnelly, J. E. Rossouw, B. M. Psaty, D. M. Herrington, J. G. Wilson, S. S. Rich, M. J. Bamshad, R. P. Tracy, L. A. Cupples, D. J. Rader, M. P. Reilly, J. A. Spertus, S. Cresci, J. Hartiala, W. H. Tang, S. L. Hazen, H. Allayee, A. P. Reiner, C. S. Carlson, C. Kooperberg, R. D. Jackson, E. Boerwinkle, E. S. Lander, S. M. Schwartz, D. S. Siscovick, R. McPherson, A. Tybjaerg-Hansen, G. R. Abecasis, H. Watkins, D. A. Nickerson, D. Ardissino, S. R. Sunyaev, C. J. O'Donnell, D. Altshuler, S. Gabriel, and S. Kathiresan. 2015. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. *Nature* **518**: 102-106.

18.   Hubacek, J. A., V. Adamkova, M. Prusikova, M. Snejdrlova, K. Hirschfeldova, V. Lanska, R. Ceska, and M. Vrablik. 2009. Impact of apolipoprotein A5 variants on statin treatment efficacy. *Pharmacogenomics* **10**: 945-950.

19.   O'Brien, S. E., S. J. Schrodi, Z. Ye, M. H. Brilliant, S. S. Virani, and A. Brautbar. 2015. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region. *J Cardiovasc Pharmacol* **66**: 183-188.

20.   Stone, N. J., J. G. Robinson, A. H. Lichtenstein, C. N. Bairey Merz, C. B. Blum, R. H. Eckel, A. C. Goldberg, D. Gordon, D. Levy, D. M. Lloyd-Jones, P. McBride, J. S. Schwartz, S. T. Shero, S. C. Smith, Jr., K. Watson, P. W. Wilson, K. M. Eddleman, N. M. Jarrett, K. LaBresh, L. Nevo, J. Wnek, J. L. Anderson, J. L. Halperin, N. M. Albert, B. Bozkurt, R. G. Brindis, L. H. Curtis, D. DeMets, J. S. Hochman, R. J. Kovacs, E. M. Ohman, S. J. Pressler, F. W. Sellke, W. K. Shen, S. C. Smith, Jr., G. F. Tomaselli, and G. American College of Cardiology/American Heart Association Task Force on Practice. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* **129**: S1-45.

21.   Luo, G., L. Zheng, X. Zhang, J. Zhang, P. Nilsson-Ehle, and N. Xu. 2009. Genotyping of single nucleotide polymorphisms using base-quenched probe: a method does not invariably depend on the deoxyguanosine nucleotide. *Anal Biochem* **386**: 161-166.

22.   Graffelman, J. 2015. Exploring Diallelic Genetic Markers: The HardyWeinberg Package. *2015* **64**: 1-23.

23.   Benjamini, Y., and Y. Hochberg. 1995. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)* **57**: 289-300.

24.   Champely, S. 2015. pwr: Basic Functions for Power Analysis. *R package version 1.1-3.* http://CRAN.R-project.org/package=pwr.

25.   Ridker, P. M., S. Mora, L. Rose, and J. T. S. Group. 2016. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. *Eur Heart J* **37**: 1373-1379.

26.   Cholesterol Treatment Trialists, C., B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E. H. Barnes, M. Voysey, A. Gray, R. Collins, and C. Baigent. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* **380**: 581-590.

27.   Team, R. C. 2015. R: A language and environment for statistical computing. *R Foundation for Statistical Computing, Vienna, Austria.* http://www.R-project.org/.

28.   Jiang, C. Q., B. Liu, B. M. Cheung, T. H. Lam, J. M. Lin, Y. Li Jin, X. J. Yue, K. L. Ong, S. Tam, K. S. Wong, B. Tomlinson, K. S. Lam, and G. N. Thomas. 2010. A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese. *Eur J Hum Genet* **18**: 1255-1260.

29.   Ballantyne, C. M., M. Bertolami, H. R. Hernandez Garcia, D. Nul, E. A. Stein, P. Theroux, R. Weiss, V. A. Cain, and J. S. Raichlen. 2006. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. *Am Heart J* **151**: 975 e971-979.

30.   Nilsson, S. K., A. Lookene, J. A. Beckstead, J. Gliemann, R. O. Ryan, and G. Olivecrona. 2007. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. *Biochemistry* **46**: 3896-3904.

31.   De Caterina, R., P. J. Talmud, P. A. Merlini, L. Foco, R. Pastorino, D. Altshuler, F. Mauri, F. Peyvandi, D. Lina, S. Kathiresan, L. Bernardinelli, D. Ardissino, and A. Gruppo Italiano. 2011. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. *Atherosclerosis* **214**: 397-403.

32.   Karlson, B. W., M. K. Palmer, S. J. Nicholls, P. Lundman, and P. J. Barter. 2016. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. *Eur J Prev Cardiol* **23**: 744-747.

33.   McTaggart, F. 2003. Comparative pharmacology of rosuvastatin. *Atheroscler Suppl* **4**: 9-14.

34.   Schachter, M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fundam Clin Pharmacol* **19**: 117-125.

35.   Martin, P. D., M. J. Warwick, A. L. Dane, S. J. Hill, P. B. Giles, P. J. Phillips, and E. Lenz. 2003. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. *Clin Ther* **25**: 2822-2835.

36.   Kivisto, K. T., M. Niemi, E. Schaeffeler, K. Pitkala, R. Tilvis, M. F. Fromm, M. Schwab, M. Eichelbaum, and T. Strandberg. 2004. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. *Pharmacogenetics* **14**: 523-525.

37.   Ballantyne, C. M., J. S. Raichlen, and V. A. Cain. 2008. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. *Journal of the American College of Cardiology* **52**: 626-632.

38.   Brunzell, J. D., M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum. 2008. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. *Journal of the American College of Cardiology* **51**: 1512-1524.

39.   Giacomini, K. M., C. M. Brett, R. B. Altman, N. L. Benowitz, M. E. Dolan, D. A. Flockhart, J. A. Johnson, D. F. Hayes, T. Klein, R. M. Krauss, D. L. Kroetz, H. L. McLeod, A. T. Nguyen, M. J. Ratain, M. V. Relling, V. Reus, D. M. Roden, C. A. Schaefer, A. R. Shuldiner, T. Skaar, K. Tantisira, R. F. Tyndale, L. Wang, R. M. Weinshilboum, S. T. Weiss, I. Zineh, and N. Pharmacogenetics Research. 2007. The pharmacogenetics research network: from SNP discovery to clinical drug response. *Clin Pharmacol Ther* **81**: 328-345.

Table 1. Baseline characteristics summarized by statin treatment and *APOA5* genotypes, respectively.

Characteristics	Statin treatment[a]				*APOA5* genotype[a]		
	Atorvastatin	Rosuvastatin	Simvastatin	P^b	T(C)/C	T/T	P^e
n	36/29[d]	30/35[d]	38/27[d]	0.342[c]	104	91	-
Male (%)	53.8	44.6	49.2	0.575[c]	45.2	53.8	0.288[c]
Age (years)	74.9±10.5	75.0±11.8	69.8±17.4	0.344	72.8±12.8	73.7±14.8	0.420
BMI (kg/m^2)	23.5±3.2	23.5±3.3	23.4±3.2	0.938	23.5±3.5	23.3±2.8	0.662
Tc (mg/dl)	193.1±49.5	180.2±40.6	186.7±49.0	0.306	191.9±45.3	180.7±47.6	0.093
Tg (mg/dl)	180.1±110.5	162.6±102.6	181.9±138.0	0.482	193.7±124.8	153.4±105.8	0.004
HDLc (mg/dl)	42.1±9.9	44.1±10.4	44.6±11.5	0.458	43.1±10.7	44.1±10.6	0.513
LDLc (mg/dl)	132.2±42.9	125.8±34.8	125.7±41.1	0.780	134.7±40.6	120.1±37.3	0.015
ApoA1 (mg/dl)	114.4±20.6	119.1±23.3	116.9±20.1	0.515	116.3±22.0	117.3±20.7	0.708
ApoB-100 (mg/dl)	86.3±31.2	86.5±25.0	94.1±29.2	0.181	92.1±28.6	85.4±28.5	0.145
ApoE (mg/dl)	4.4±1.5	3.8±1.0	4.5±1.4	0.019	4.4±1.3	4.2±1.3	0.382
FFA (mmol/l)	0.5±0.2	0.5±0.3	0.5±0.2	0.780	0.5±0.2	0.4±0.3	0.052
Lp(a) (mg/dl)	17.5±17.0	18.0±15.4	19.8±17.9	0.916	18.4±14.8	18.4±18.8	0.575
Type 2 diabetes (%)	43.1	40.0	32.3	0.430[c]	40.4	36.3	0.658[c]

[a]Continuous variables are expressed as mean ±standard deviations (sd);
[b]*P* values were estimated by Krukskal-Wallis test for continuous variables;
[c]*P* values were estimated by Chi-square test for categorical variables;
[d]Sample sizes for individuals genotyped as T(C)/C and T/T, respectively;
[e]*P* values were estimated by Wilcox rank-sum test for continuous variables;

Figure legends

Fig. 1. *APOA5*-statin interactions. (A) Box plots (with median) showing percentage changes in the indicated biomarkers after treatment with rosuvastatin (5-10 mg per day), atorvastatin (10-20 mg per day) or simvastatin (40 mg per day). *, $P<0.05$; **, $P<0.01$; ***, $P<0.001$ versus before treatment. (Wilcoxon signed-rank test) (B-E) Box plots (with median) showing percentage changes in total cholesterol (Tc) (B), LDLc (C), HDLc (D), and triglycerides (Tg) (E) in response to each statin in subjects divided by genotype (*APOA5* rs662799 T(C)/C and T/T). Sample sizes for each subgroup are given on top of panels B-E. *, $P<0.05$; **, $P<0.01$ (Wilcoxon rank-sum test).

Fig. 2. Both *APOA5* and statin alter the ApoB-LDLc correlations. Correlations between ApoB and LDLc before (A) and after (B) statin treatment in subjects with *APOA5* rs662799 T(C)/C or T/T allele.

Before treatment

A

rho=0.55(P<0.001)
rho=0.78(P<0.001)

● T(C)/C
● T/T

LDLc (mg/dl)

ApoB (mg/dl)

After treatment

B

rho=0.50(P<0.001)
rho=0.44(P<0.001)

● T(C)/C
● T/T

LDLc (mg/dl)

ApoB (mg/dl)